Navigation Links
New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

oved by the FDA," said Charles Baum, MD, vice president of Pfizer Global Research and Development. "We are committed to investigating the role SUTENT may play in the treatment of advanced breast cancer through a comprehensive phase III program."

SUTENT (sunitinib malate) Phase III Trials in Breast Cancer

This phase III research program in advanced breast cancer will investigate sunitinib malate in multiple settings, including first, second and later lines, as both a single agent and in various combinations, including: combined with standard of care (SOC) chemotherapies versus SOC chemotherapies alone and combined with SOC chemotherapies versus other targeted therapies. The studies will evaluate sunitinib malate in patients with various types of advanced breast cancer including HER2 negative and positive, and previously treated advanced triple receptor negative (ER-, PR- and HER2-).

The phase II and III randomized, open-label studies that are currently enrolling include:

Phase III

-- SUN 1094: Sunitinib malate + paclitaxel versus bevacizumab + paclitaxel in first-line advanced breast cancer

-- SUN 1064: Sunitinib malate + docetaxel versus docetaxel alone in HER2- advanced breast cancer

-- SUN 1099: Sunitinib malate + capecitabine versus capecitabine alone in previously treated advanced breast cancer

-- SUN 1107: Single-agent sunitinib malate versus capecitabine in previously treated advanced breast cancer

Phase II

-- SUN 1077: Single-agent sunitinib malate versus chemotherapy in previously treated advanced triple receptor negative (ER-, PR-, and HER2-) breast cancer

-- SUN 1067: Sunitinib malate + trastuzumab versus trastuzumab + placebo in advanced breast cancer

About SUTENT(R) (sunitinib malate)

SUTENT is a multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolera
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
(Date:7/23/2008)...Company Focused on IND-Enabling Work with Protein ...athway of Complement System, CAMBRIDGE, Mass., Ju...day announced it has initiated a corporate growth ..., as chief executive officer and the,establishment...ker succeeds,Woodruff Emlen, M.D., a co-founder of...
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Psoriasis Study Showing Increased Risk of Death Underscores Need for More Research Group Says 8476 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 2MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 3Synthetech Earns National Recognition for Performance Improvement Program 2270 1Synthetech Earns National Recognition for Performance Improvement Program 2270 2Synthetech Earns National Recognition for Performance Improvement Program 2270 3Researchers hope to provide chronic fatigue syndrome answers 8470 1Researchers hope to provide chronic fatigue syndrome answers 8470 2
...History Highlighted in AACR Cancer Journal , AUSTI...Therapeutics, Inc. (NASDAQ:INGN) announced today t...nical benefit of its lead product,Advexin in a pat...,Li-Fraumeni Syndrome (LFS), a genetic disorder ch...r suppressor gene. This is the,first reported trea...
...LLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn,P...tical company,dedicated to the discovery, developm...s for cancer, central nervous system disorders,se...day announced,that Dr. John Marshall, Principal In...y,s lead cancer compound RX-0201 (Archexin),will ...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4
(Date:7/25/2008)...ne is supporting the US Department of Defense and ...olden Phoenix. Operation Golden Phoenix is a, fo...designed to assist, federal, state and local agenc...enarios. Dataline is providing a vital, ad-hoc, se...dical use during the exercise., NORFOLK, Va., Jul...
(Date:7/25/2008)...HAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pha...rmaceutical company, today announced that it,has l... antiarrhythmic,indicated for the treatment and pr...illation and hemodynamically unstable ventricular,...gular heart beat.,Sagent,s amiodarone HCl injectio...
(Date:7/25/2008)...finds fluid back-up in esophagus can cause immune ...thDay News) -- The first evidence linking gastroes... discovered by Duke University Medical Center rese...tions was first noted in the 1970s, and since then... percent of asthma patients also experience GERD s...
(Date:7/25/2008)... Whether you are an Olympian, P...ior, there are Five Things You Need to Know about ...I.S.C. Spine and Sports Center , ...08 -- America,s premier athletes are heading to Be...oning and sacrifice in the hopes of capturing an O...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
... Industries Ltd today said it has acquired a signi...ary of US-based indigene Pharma Inc// , for an und...iopharmaceuticals, has been in the business of bot... healthcare products. Commenting on the strategic...
...discovery may help treat stroke-affected humans Ne...s recover after a stroke by stimulating a protein/...pes about the possibility of repairing the human b...h as stroke or spinal-cord damages. The findings ...
...ciate Health Minister Jim Anderton said that the G... people in all age groups//. New Zealand has a ve...given to bring down youth suicide rates. According...ms in 2003 were aged 25 or older. Suicide rates am...
...archers have concluded that earlier a deaf child r...r spoken language skills, sentence formation and u...deaf but used cochlear implants, able to hear part...he right time to make use of it. In contrast, a c...
Other Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: